期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 19, 期 8, 页码 1318-1321出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v19.i8.1318
关键词
Hepatitis B virus; Chronic myeloid leukemia; Imatinib mesylate; Nilotinib; Tyrosine kinase inhibitor
Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not been reported in the English literature. We report here 2 cases of HBV reactivation in chronic myeloid leukemia patients receiving imatinib mesylate and a novel case of nilotinib related HBV reactivation. (C) 2013 Baishideng. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据